Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

[News]

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).

More... (http://www.news-medical.net/news/20100106/Enzon-Pharmaceuticals-treats-first-patient-in-Phase-2-studies-of-PEG-SN38.aspx)